SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION																	
					Washington, D.C. 20549										OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					ENT OF CHANGES IN BENEFICIAL OWNERSHIP									Estima	OMB Number: 3235-0287 Estimated average burden hours per response: 0.5		
Instruc	tion 1(b).			File					 a) of the Secure Investment C 			934					
1. Name and Address of Reporting Person* MILANO VINCENT						2. Issuer Name and Ticker or Trading Symbol Aclaris Therapeutics, Inc. [ACRS]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (rive title Other (openity)			Dwner	
	/O ACLARIS THERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 06/03/2021							Officer (give title Other (specify below) below)				
640 LEE ROAD, SUITE 200					4.1								ndividual or Joint/Group Filing (Check Applicable				
(Street) WAYNE													ne) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State) (Zip)																
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
Date				2. Trans Date (Month/		ear) I	2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Dispose Code (Instr. 5)		ities Acquired (A) or d Of (D) (Instr. 3, 4 and		Beneficia	es Form ally (D) of following (I) (I	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
									Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)		(Instr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Da Security or Exercise (M		3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr 8)		5. Number n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Direct (D or Indire (I) (Instr.	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$21.9	06/03/2021			A		12,250		(1)(2)	06/02/2031	Common Stock	12,250	\$0.00	12,250	D		
Restricted Stock Units	(3)	06/03/2021			A		3,356		(1)(4)	(4)	Common Stock	3,356	\$0.00	3,356	D		

Explanation of Responses:

1. This grant was made pursuant to the issuer's fifth amended and restated non-employee director compensation policy.

2. The shares subject this option will vest in twelve equal monthly installments commencing July 3, 2021, subject to Reporting Person's continuous service through each such date.

3. Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.

4. The shares underlying these restricted stock units will vest on June 3, 2022, subject to the Reporting Person's continuous service through such date.

Remarks:

/s/ Mark Ballantyne, Attorneyin-Fact 06/04/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.